Pharmaceutical segment sales exceeded our estimates of $12.62 billion. Excluding the impact of all acquisitions and divestitures and currency, on an adjusted operational basis, worldwide sales rose 7.2%.
Pharmaceutical segment sales rose 4.2% year over year to $13.41 billion, reflecting a 7.2% operational increase and a 3% negative currency impact.
Excluding the impact of all acquisitions and divestitures, on an adjusted operational basis, international sales rose 7.9% in the quarter.
J and jstock plus#
International sales rose 1.8% on a reported basis to $12.23 billion, reflecting an operational increase of 8.3%, plus a negative currency impact of 6.5%. Organically, excluding the impact of acquisitions and divestitures, sales rose 7.6% on an operational basis compared with an 0.8% increase in the previous quarter.įirst-quarter sales in the domestic market rose 9.7% to $12.52 billion. Sales also beat our estimates of $23.6 billion. Sales rose 5.6% from the year-ago quarter, reflecting an operational increase of 9% and a negative currency impact of 3.4%. Sales of this drug and consumer products giant came in at $24.75 billion, beating the Zacks Consensus Estimate of $23.57 billion. Including these items, J&J reported first-quarter loss of 3 cents per share, down 101.6% from the year-ago quarter. Earnings rose 0.4% from the year-ago period.Īdjusted earnings exclude intangible amortization and some other special items. Johnson & Johnson ’s ( JNJ Quick Quote JNJ - Free Report) first-quarter 2023 earnings came in at $2.68 per share, which beat the Zacks Consensus Estimate of $2.51 as well as our estimate of $2.49 per share.
0 kommentar(er)
